Management of bleeding events and invasive procedures in patients with haemophilia A without inhibitors treated with emicizumab

A consensus statement of the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network

Fontana Pierre\(^{a}\), Alberio Lorenzo\(^{b}\), Albisetti Manuela\(^{c}\), Angelillo-Scherrer Anne\(^{d}\), Asmis Lars M.\(^{e}\), Casini Alessandro\(^{f}\), Gerber Bernhard\(^{g}\), Graf Studt\(^{h}\), Hegemann Inga\(^{i}\), Korte Wolfgang\(^{g}\), Martinez Maria\(^{j}\), Studt Jan-Dirk\(^{h}\), Tsakiris Dimitrios A.\(^{a}\), Wuillemin Walter A.\(^{a}\), Kremer Hovinga Johanna A.\(^{a,d}\)

\(^{a}\) Division of Angiology and Haemostasis, University Hospitals of Geneva, Switzerland
\(^{b}\) Service and Central Laboratory of Haematology, Lausanne University Hospital, Lausanne, Switzerland
\(^{c}\) Division of Haematology, University Children’s Hospital, Zurich, Switzerland
\(^{d}\) Department of Haematology and Central Haemostasis Laboratory, Inselspital, Bern University Hospital, University of Bern, Switzerland
\(^{e}\) Centre for perioperative Thrombosis and Haemostasis, Zurich, Switzerland
\(^{f}\) Clinic of Haematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
\(^{g}\) Cantonal Hospital of St Gallen, Switzerland
\(^{h}\) Department of Medical Oncology and Haematology, University Hospital Zurich, Switzerland
\(^{i}\) Diagnostic Haematology, Basel University Hospital, Basel, Switzerland
\(^{j}\) Division of Hematology and Central Hematology Laboratory, Cantonal Hospital of Lucerne, Lucerne, and University of Bern, Switzerland

Summary

INTRODUCTION: Emicizumab (Hemlibra\(^{®}\), Hoffmann-La Roche, Switzerland) is now available for haemophilia A patients with or without factor VIII inhibitors. Management of bleeding events and replacement therapy for invasive procedures have to be adapted.

OBJECTIVE: To provide a practical guidance for the management of breakthrough bleeding events and elective or urgent surgery in adult and paediatric patients with haemophilia A without inhibitors treated with emicizumab.

METHODS: Based on the available literature and the experiences collected from adult and paediatric patients treated in Switzerland, the Working Party on Haemostasis of the Swiss Society of Haematology and the Swiss Haemophilia Network worked together to reach a consensus on the management of bleeding events and invasive procedures.

RESULTS AND CONCLUSION: Minor bleeding events and invasive procedures associated with low bleeding risk can be treated without factor replacement therapy in most cases, whereas major bleeding events and high-risk surgery require additional factor VIII replacement at usual doses, at least for the first days. Emicizumab treatment should be continued throughout the procedure and during the postoperative period. Elective major surgery should be planned according to emicizumab dosing for patients with a once-a-month posology. Of note, so far only few data are available on the management of major bleeds and surgery in patients with haemophilia A treated with emicizumab and this practical guidance will have to be regularly updated with growing experience.

Keywords: emicizumab, bleeds, invasive procedures, guidelines

Introduction

Emicizumab (Hemlibra\(^{®}\), Hoffmann-La Roche, Basel, Switzerland) is a recombinant, humanised bispecific monoclonal antibody that substitutes for the pro-coagulant role of factor VIII by bridging factor IXa to factor X. It is licensed for prophylactic treatment in patients with congenital (usually severe) haemophilia A, with or without factor VIII inhibitors. Emicizumab can be administered subcutaneously and has a half-life of approximately 30 days. This allows a dosing of 1.5 mg/kg bodyweight once a week, or 3 mg/kg every two weeks, or 6 mg/kg once a month after an initial weekly loading dose of 3 mg/kg for four consecutive weeks. The average effective plasma concentration reached is around 50 µg/ml [1, 2]. Although the number of spontaneous bleeds are dramatically decreased in patients on emicizumab, breakthrough bleeds may still occur, and invasive procedures including surgery may be necessary. Guidelines for the management of bleeds and invasive procedures in patients treated with emicizumab and factor VIII inhibitors are available, and rely mostly on recombinant factor VIIa to restore haemostasis [3–5]. However, specific recommendations for haemophilia A patients without inhibitors treated with emicizumab, who may need factor
VIII concentrates to treat breakthrough bleeds or prior to invasive procedures, are scarce [6].

Methods
Our practical guidance is based on the available literature and experiences with patients treated in Switzerland. Two authors (PF and JAKH) reviewed the literature available in PubMed using “emicizumab” as a keyword, as well as relevant abstracts presented at major congresses (the American Society of Hematology, the European Association for Haemophilia and Allied Disorders, the International Society on Thrombosis and Haemostasis and Gesellschaft für Thrombose- und Hämostaseforschung) during the past three years, and abstracts on file from Roche (last updated 30 June 2020). A first draft of the proposals was then circulated and a consensus among all authors was reached.

Breakthrough bleeding events
Emicizumab does not fully restore haemostasis and patients may face bleeding events after (even minor) trauma or, rarely, spontaneously. Patients treated with emicizumab should have factor VIII concentrate available for emergency situations. However, factor VIII treatment is not always necessary, and depends on the severity of the bleed, on its localisation and on the possibility of specific local treatment, such as compression or endoscopic procedures. Notably, the amount of on-demand factor VIII used per bleeding episode was comparable in a subset of 48 patients during the non-interventional study period prior to study enrolment and on study in the HAVEN 3 trial [7]. This suggests that for most bleeds, factor VIII replacement therapy followed the same dosing as before switching to emicizumab. Breakthrough bleeding events and their treatment should be documented and recorded, for example in a national haemophilia registry by the treating haemophilia centre (NCT02512250). The treatment with emicizumab must not be interrupted and the posology should not be altered if a bleed occurs, provided that the dose and administration frequency are correct. Breakthrough bleeding events, particularly spontaneous bleeds, may raise the issue of poor efficacy of emicizumab prophylactic treatment. Poor adherence with many missed injections over weeks might be possible. Anti-drug antibodies [8] have been rarely described [9] and have not been associated with the occurrence of clinical events up to now. When decreased efficacy of the drug is a concern, the activated partial thromboplastin time (aPTT) can be measured, although, because of the oversensitivity of the aPTT for emicizumab, a prolonged aPTT will only occur at very low emicizumab plasma concentrations [10]. Studying thrombin generation may be an option, but no association with clinical efficacy of emicizumab has been reported [4]. Finally, the determination of emicizumab plasma concentration using dedicated calibrators may be helpful [11, 12], and concentrations below 40 μg/ml should be a concern, especially with once-a-week or every two weeks dosing [2]. Of note, the lower limit of a proposed “efficacious” range has been evaluated as 30 μg/ml [13]. Management of breakthrough bleeding events is summarised in figure 1.

Minor bleeding events
For mucosal bleeds, tranexamic acid alone should be prescribed (2–4.5 g/24h for adults in two or three intakes, and 20–25 mg/kg/dose every 6–8 hours for children) for 1–3 days. In the case of minor traumatic bleeds, administration of a single dose of a factor VIII concentrate (30–50 IU/kg) should be considered, followed by a clinical evaluation 24 hours later. For target joint bleeds, although a single dose of factor VIII concentrate may be sufficient in patients with minimal joint damage, more intensive replacement therapy may be required in patients with advanced joint disease.

Major bleeding events
Major bleeds, defined according to the ISTH criteria [14], such as large muscle haematomas, bleeds associated with a drop in haemoglobin ≥20 g/l and/or necessitating a transfusion with at least two units of packed red blood cell concentrate, life-threatening bleeds or a bleed in a critical organ must be immediately treated with an initial dose of 40–50 IU/kg of a factor VIII concentrate. Adherence to emicizumab treatment should be questioned in the event of a spontaneous major bleeding event and evaluation of the emicizumab plasma concentration is desirable. Timing and doses of the subsequent treatment should be adapted to the type of bleed, the factor used (standard or extended half-life) and the clinical course by maintaining a factor VIII trough level of 0.6–0.8 IU/ml for at least the first 48 hours. If the bleed is under control, a lower dose replacement therapy regimen may be prescribed (providing that adherence to emicizumab is not an issue) for up to 10 days after the major bleed. Tranexamic acid may be considered as an additional treatment. Of note, in cases of severe bleeds with massive transfusion, the plasma concentration of emicizumab may decrease because of loss of the compound due to bleeding and dilution with fluids and plasma re...

\[\text{Figure 1: Summary of the proposed management of breakthrough bleeding events in persons with haemophilia A factor VIII without inhibitors and treated with emicizumab. ADA = anti-drug antibody.}\]

\[
\begin{align*}
\text{Minor bleeding events} & \\
- & \text{Check adherence to treatment} \\
- & \text{Consider biological evaluation if adherence is a concern (aPTT, emicizumab plasma concentration)} \\
- & \text{Consider a single FVIII dose (30–50 IU/kg)} \\
- & \text{Tranexamic acid if mucosal bleeding} \\
- & \text{Clinical evaluation at 24h}
\end{align*}
\]

\[
\begin{align*}
\text{Major bleeding events} & \\
- & \text{Check adherence to treatment} \\
- & \text{aPTT and emicizumab plasma concentration} \\
- & \text{FVIIa 40–50 IU/kg and maintain a trough level of 0.6–0.8 IU/ml during 48h} \\
- & \text{Adherence is a concern or evidence of ADA} \\
- & \text{Yes} \\
- & \text{FVIII replacement therapy} \\
- & \text{Consider lower intensity FVIII replacement therapy if bleeding is controlled after 48h} \\
- & \text{No}
\end{align*}
\]
placement therapy, and assessing emicizumab concentration should be considered.

Of note, monitoring of actor VIII levels in patients treated with emicizumab requires a chromogenic factor VIII assay containing bovine factor X since emicizumab interferes with one stage aPTT-based coagulation assays and with chromogenic assays using human coagulation proteins [13].

**Invasive procedure and surgery**

Invasive procedures or surgery may be necessary, whether elective or emergency. In any case, the treatment with emicizumab must not be interrupted or the posology altered, provided that the dose and administration frequency are correct. We suggest that an elective procedure should be planned independently of the last emicizumab injection, except for patients with a once-a-month posology and elective surgery associated with a high bleeding risk. Once-a-month dosing is associated with emicizumab peaks and troughs levels ranging from approximately 30–60 µg/ml [2]. Therefore, the consensus is to perform high-risk elective surgery within 10 days after an emicizumab injection. An alternative would be to switch from a once-a-month posology to a once-a-week or once every other week regimen 1 month before the procedure and for 2 weeks thereafter. Clinical experience up to now includes mostly low-risk procedures. However, a few cases of major surgeries have been described with favourable outcome with factor VIII replacement therapy. Management of invasive procedures is summarised in figure 2.

**Low-risk invasive procedures and minor surgery**

In the HAVEN 1–4 trials, 214 minor surgeries were performed in 113 study participants (108 minor surgeries performed in patients without inhibitors), including 63 dental procedures – mostly removal of central venous access devices in children (16/27 procedures) – and were usually performed with a single dose of factor VII-III concentrate prior to surgery, with two bleeding complications leading to one additional factor VIII infusion. No thrombotic events occurred. Altogether, emicizumab seems to confer good haemostatic coverage for minor surgeries, often even without the necessity for coagulation factor administration.

For minor invasive procedures, including dental care, dental avulsions, endoscopic procedures without biopsy and joint infiltration, we suggest abstaining from prior factor VIII product administration. Tranexamic acid should be prescribed, at least for all dental procedures. If the bleeding risk is a concern (e.g., in endoscopic procedures with biopsy, multiple dental avulsions), a factor VIII dose of 30 IU/kg 30 minutes to 1 hour before the procedure can be considered.

**High-risk invasive procedures and major surgery**

In the HAVEN 1–4 trials, 19 major surgeries (including 8 major orthopaedic surgeries) were performed in 19 participants (including 8 patients without inhibitors) [15]. Most of these interventions were performed under prophylactic coagulation factor replacement, with postoperative bleeding in only one patient, and there were no thrombotic complications. For arthroplasty (hip or knee) in patients without inhibitors (n = 3), prophylaxis with factor VIII concentrates was used for 7, 16 and 19 days [15]. In the HAVEN 3 study, four patients had major orthopaedic surgery and the mean cumulative factor VIII replacement therapy was 135 IU/kg in the first 2 days after surgery, and 148 IU/kg over the following 5 days, suggesting decreased trough levels from day 3 after surgery [1, 15]. More recently, a single-centre experience of surgery in 122 children and adult patients treated with emicizumab for more than 6 months showed that the majority of orthopaedic surgeries were performed with an initial factor VIII dose of 50 IU/kg prior to surgery, replacement therapy once or twice a day (usually 50 IU/kg) for the following 2 to 5 days and lower-intensity replacement therapy thereafter [18]. For major surgeries, adherence to the prophylactic treatment is of particular importance and a laboratory evaluation of emicizumab concentration, should be considered if compliance is a concern. Although poor compliance may not influence the initial factor VIII replacement therapy, it may influence factor VIII dosing during the postoperative days. We suggest administration of 40–50 IU/kg of factor VIII 30 min–1 hour before surgery and maintain a through level of 0.6–0.8 IU/ml during 48–72 h.

**Figure 2: Summary of the proposed management of invasive procedures in persons with haemophilia A without factor VIII inhibitors and treated with emicizumab.**

- **Invasive procedure**
  - Check compliance with the patient
  - Consider laboratory evaluation if compliance is a concern (aPTT, emicizumab plasma concentration)
  - Consider a single factor VIII dose (30 IU/kg) 30 min-1h before procedure
  - Tranexamic acid if mucosal surgery (e.g. dental procedures)

- **Check compliance with the patient aPTT, emicizumab plasma concentration if compliance is a concern**

- **VIII 40-50 IU/kg 30 min-1h before surgery and maintain a through level of 0.6-0.8 IU/ml during 48-72h**

- **Consider lower intensity factor VIII replacement therapy (see text for details) if compliance with emicizumab is not an issue and no bleeding, for 10-14 days after surgery**

- **Consider tranexamic acid**
be adopted (total treatment duration 10–14 days). These suggestions have to be adapted to the clinical situation and the type of surgery. Of note, in cases of severe haemorrhagic complications, the plasma concentration of emicizumab may decrease because of loss of compound due to bleeding and dilution with fluids and plasma replacement therapy, and assessing emicizumab concentration should be considered.

We suggest that thromboprophylaxis similar to that for persons with haemophilia A who are not on emicizumab should be prescribed, according to the practice of each centre.

Discussion

The management of breakthrough bleeding events and invasive procedures in patients treated with emicizumab challenges haemophilia centres. Experience is still scarce, with very few cases reported. Therefore, a common consensus and practical guidance is important to have, but also has to be updated regularly with growing experience. The management of patients treated with emicizumab requires a multidisciplinary approach and close collaboration with the haemostasis laboratory is mandatory, as in most settings involving patients with haemophilia.

Low-dose protocols for invasive procedures are considered in several situations already, including non-factor replacement therapies [21]. However, and according to the data available up to now, a lower intensity dosing is described for procedures associated with a low bleeding risk, whereas in most of the major surgeries performed in patients treated with emicizumab, factor VIII products were given at usual doses, at least during the first 48 hours. Clinical evaluation is of particular importance after major surgery in order to adapt replacement therapy. Indeed, a lower replacement dose protocol may be associated with increased bleeding complications, whereas a conventional protocol may increase the risk of venous and arterial thrombotic events, especially in geriatric patients with several comorbidities. Of note, no thrombotic event was described after major surgery up to now. In vitro studies using a thrombin generation assay showed a non-additive effect of factor VI\(\text{II}\) combined with emicizumab [22]. Indeed, emicizumab has a lower binding affinity to factor IXa and factor X than factor VIIIa and does not interfere with exogenous factor VIII binding in the intrinsic tenase complex [23], which probably contributes to its safety profile regarding thrombotic events when both treatments are prescribed. Integrative coagulation assays, such as a thrombin generation assay or thrombelastography, may be useful for the adaptation of periprocedural factor VIII replacement therapy [24] and should be included as part of research projects for optimal management of patients on emicizumab.

Acknowledgements

The authors thank Thomas Lecompte, University Hospitals of Geneva, for his critical review of the manuscript.

Potential competing interests

PF has received support for the nurses’ programme of the Haemostasis Unit from Bayer, CSL Behring, NovoNordisk, Octapharma, Roche and Sobi. LA received grants/research support from: Bayer, CSL-Behring, Novartis, NovoNordisk, Roche, Shire-Takeda, and Sobi; support for the CHUV haemophilia nurses program from: CSL-Behring, Bayer, NovoNordisk, Octapharma, Roche, Shire, and Sobi; honoraria for participating in scientific advisory boards: Bayer, Boehringer Ingelheim, Daichii Sanyko, NovoNordisk, OrPha Swiss, Pfizer, Roche, Takeda, Sobi; honoraria as consultant/speaker: Bayer, Sanofi-Genzyme, Siemens. MA received support for the haemophilia and physiotherapy nurse programme at the University Children’s Hospital, Zurich, from: Bayer, Biostest, CSL-Behring, NovoNordisk, Octapharma, Roche, and Sobi. She also participated in scientific advisory board activities for Bayer, Boehringer Ingelheim, Daichii Sanyko, Novovonordisk, Roche and Sobi. AC has received grants from CSL Behring and NovoNordisk and non-financial support from Bayer and Shire. BG reports grants and personal fees from Pfizer; personal fees and funding for accredited continuing medical education from Sanofi and Alnylam, during the conduct of the study, funding for accredited continuing medical education program from Axonlab, Bayer, Bristol Myers Squibb, Daichii Sanyko, Janssen, Mitsubishi Tanabe Pharma, NovoNordisk, Octapharma, Takeda, Sanofi, Sobi; non-financial support from Axonlab and Thermo Fisher from outside the submitted work. LG received lecture and advisory honoraria from CSL Behring, Novo Nordisk, Octapharma, Roche and Sobi. IH received lecture and advisory honoraria from Bayer, CSL Behring, NovoNordisk, Octapharma, Pfizer, Roche, Shire-Takeda and Sobi. WK received grants/research support/travel support or honoraria from: Bayer, CSL-Behring, NovoNordisk, Shire-Takeda, and Sobi. JDS received advisory and lecture honoraria from Bayer, Shire-Takeda, BMS-Pfizer, Sanofi, Siemens Diagnostics. WW received grants/research support/travel support or honoraria from: Bayer, Bristol Myers Squibb, CSL-Behring, Daichii-Sanyko, NovoNordisk, Pfizer, Sanofi and Shire-Takeda. IAKH has received a research grant from Baxter Inc, now part of Takeda group of companies, honoraria for participation in advisory boards or lectures in symposia of Bayer, CSL-Behring, NovoNordisk, Roche, Sanofi, Shire-Takeda, and Sobi are paid to her employer, Insel Gruppe AG; the support of the interprofessional haemophilia care at EHCCC Bern Inselspital by Bayer, CSL-Behring, Bayer, NovoNordisk, Octapharma, Roche, and Sobi is gratefully acknowledged. All other authors report no relevant conflict of interest.

References


